{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"182.1","value":"58000"},{"groupId":"OG001","spread":"388.5","value":"49900"},{"groupId":"OG002","spread":"78.2","value":"141000"},{"groupId":"OG003","spread":"134.2","value":"63700"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"12"}],"units":"Participants"}],"title":"AUC0-28d"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"171.7","value":"102000"},{"groupId":"OG001","spread":"165.4","value":"92900"},{"groupId":"OG002","spread":"76.7","value":"206000"},{"groupId":"OG003","spread":"61.3","value":"142000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"title":"AUC0-84d"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"12"}],"units":"Participants"}],"description":"The AUC from time zero to day 28 and 84 or other disease assessment days, in peripheral blood. AUC0-28d and AUC0-84d, based on the transgene level data by qPCR, were summarized by Month 3 response, per Independent Review Committee assessment.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Novartis manufacturing facility in Morris Plains, US.","id":"OG000","title":"Tisagenlecleucel - CR/PR"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Novartis manufacturing facility in Morris Plains, US","id":"OG001","title":"Tisagenlecleucel - Main Cohort: SD/PD/UNK"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Fraunhofer Institut für Zelltherapie, Leipzig, Germany.","id":"OG002","title":"Tisagenlecleucel - Cohort A: CR/PR"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Fraunhofer Institut für Zelltherapie, Leipzig, Germany.","id":"OG003","title":"Tisagenlecleucel - Cohort A: SD/PD/UNK"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Full Analysis Set (FAS): Comprised all patients who received infusion of tisagenlecleucel with valid PK assessments.","reportingStatus":"POSTED","timeFrame":"0 - 28 days after infusion for AUC0-28d, 0 - 84 days after infusion for AUC0-84d","title":"Pharmacokinetics (Pk): AUC0-28d and AUC0-84d","type":"SECONDARY","unitOfMeasure":"copies/ug*days"}